FindMyKOL

Barry Rayburn, MD

Basic profile

University of Alabama at Birmingham

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBirmingham, AL · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: RegionalLatest publication2012Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Barry Rayburn is a Cardiology physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 83 publications with 3,903 citations (h-index 29).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
83publications

Publications indexed by OpenAlex. Counts exclude supporting files.

3,903citations

Citations across these publications.

29h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
13companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Bayer
    Program year20256 paymentsResearch
    $7,658
  • PFIZER INC.
    Program year20252 payments
    $42
  • Alnylam Pharmaceuticals Inc.
    Program year20251 payment
    $20
All 18 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    77%
    Beta blocker16.8%
    Carvedilol40%Metoprolol Succinate32%Metoprolol Tartrate17%Atenolol4%Sotalol4%Pindolol2%Propranolol Hcl Er1%Labetalol Hcl1%
    Part D<11 patients
    Statin9.8%
    Atorvastatin Calcium59%Rosuvastatin Calcium34%Pravastatin Sodium4%Simvastatin2%Livalo2%
    Part D<11 patients

    + 21 more classes in this area

  • Blood & clotting

    15.4%
    Factor Xa inhibitor9.9%
    Eliquis89%Xarelto11%
    Part D≥142 patients
    P2Y12 inhibitor3.2%
    Clopidogrel100%
    Part D≥73 patients

    + 4 more classes in this area

  • Genitourinary & hormones

    4.4%
    Phosphodiesterase 5 Inhibitor4.4%
    Sildenafil Citrate71%Tadalafil29%
    Part D≥48 patients
Where care is delivered (Part B)16.4% facility · 83.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”